Total Payments
$2,829
2024 Payments
$14.64
Companies
14
Transactions
107
Medicare Patients
1,819
Medicare Billing
$524,194
Payment Breakdown by Category
Food & Beverage$2,541 (89.8%)
Education$287.77 (10.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,541 | 98 | 89.8% |
| Education | $287.77 | 9 | 10.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $661.07 | 20 | $0 (2024) |
| ViiV Healthcare Company | $431.91 | 16 | $0 (2021) |
| Allergan Inc. | $407.13 | 22 | $0 (2019) |
| Janssen Products, LP | $379.45 | 4 | $0 (2021) |
| VYERA PHARMACEUTICALS, LLC | $219.91 | 16 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $163.24 | 11 | $0 (2020) |
| Insmed, Inc. | $143.63 | 1 | $0 (2019) |
| AngioDynamics, Inc. | $143.01 | 1 | $0 (2021) |
| Astellas Pharma US Inc | $103.22 | 3 | $0 (2019) |
| Janssen Biotech, Inc. | $94.44 | 9 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14.64 | 1 | Gilead Sciences, Inc. ($14.64) |
| 2023 | $62.16 | 3 | Gilead Sciences, Inc. ($41.26) |
| 2022 | $30.86 | 1 | Gilead Sciences, Inc. ($30.86) |
| 2021 | $444.28 | 9 | ViiV Healthcare Company ($202.27) |
| 2020 | $119.61 | 8 | Merck Sharp & Dohme Corporation ($45.86) |
| 2019 | $851.98 | 31 | Allergan Inc. ($195.35) |
| 2018 | $719.84 | 24 | Gilead Sciences, Inc. ($452.02) |
| 2017 | $585.28 | 30 | Janssen Products, LP ($176.30) |
All Payment Transactions
107 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.64 | General |
| 05/03/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.92 | General |
| 04/03/2023 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: HIV | ||||||
| 02/23/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.34 | General |
| 06/02/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.86 | General |
| 12/14/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $12.56 | General |
| Category: HIV | ||||||
| 11/19/2021 | Janssen Products, LP | SYMTUZA (Drug) | Education | In-kind items and services | $99.00 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 11/11/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $112.13 | General |
| Category: HIV | ||||||
| 11/03/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $8.31 | General |
| Category: HIV | ||||||
| 10/26/2021 | AngioDynamics, Inc. | AngioVac (Device) | Food and Beverage | In-kind items and services | $143.01 | General |
| Category: ET | ||||||
| 10/07/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $6.00 | General |
| Category: HIV | ||||||
| 09/08/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $27.88 | General |
| Category: HIV | ||||||
| 08/23/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: HIV | ||||||
| 08/04/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: HIV | ||||||
| 09/25/2020 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $11.68 | General |
| Category: HIV | ||||||
| 08/19/2020 | VYERA PHARMACEUTICALS, LLC | Daraprim (Drug) | Food and Beverage | In-kind items and services | $15.57 | General |
| Category: Toxoplasmosis | ||||||
| 06/11/2020 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: HIV | ||||||
| 06/10/2020 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $11.69 | General |
| Category: HIV | ||||||
| 03/11/2020 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: ANTIBIOTIC | ||||||
| 02/19/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/15/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $14.48 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/15/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/05/2019 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $2.49 | General |
| Category: HIV | ||||||
| 11/18/2019 | Vyera Pharmaceuticals, LLC | Daraprim 30 Tablet in 1 Bottle (Drug) | Food and Beverage | In-kind items and services | $24.84 | General |
| Category: Toxoplasmosis | ||||||
| 11/06/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 427 | 1,769 | $273,675 | $146,311 |
| 2022 | 6 | 618 | 1,827 | $304,225 | $149,874 |
| 2021 | 4 | 225 | 674 | $126,000 | $63,402 |
| 2020 | 7 | 549 | 1,848 | $339,100 | $164,606 |
Total Patients
1,819
Total Services
6,118
Medicare Billing
$524,194
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 124 | 759 | $132,825 | $73,919 | 55.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 194 | 886 | $110,750 | $57,274 | 51.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 62 | 71 | $14,200 | $7,599 | 53.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 47 | 53 | $15,900 | $7,520 | 47.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 151 | 857 | $149,975 | $71,929 | 48.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 194 | 642 | $80,250 | $37,505 | 46.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 115 | 124 | $37,200 | $20,204 | 54.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 119 | 131 | $26,200 | $14,549 | 55.5% |
| 99305 | Initial nursing facility visit per day, typically 35 minutes | Facility | 2022 | 28 | 33 | $6,600 | $3,442 | 52.2% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 11 | 40 | $4,000 | $2,244 | 56.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 104 | 472 | $82,600 | $40,511 | 49.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 88 | 99 | $29,700 | $16,412 | 55.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 22 | 92 | $11,500 | $5,513 | 47.9% |
| 99305 | Initial nursing facility visit, typically 35 minutes per day | Facility | 2021 | 11 | 11 | $2,200 | $967.05 | 44.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 205 | 1,340 | $234,500 | $110,537 | 47.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 149 | 171 | $51,300 | $27,815 | 54.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 91 | 100 | $20,000 | $10,955 | 54.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 49 | 174 | $21,750 | $10,071 | 46.3% |
| 99305 | Initial nursing facility visit, typically 35 minutes per day | Facility | 2020 | 33 | 33 | $6,600 | $3,393 | 51.4% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Facility | 2020 | 11 | 14 | $1,750 | $1,013 | 57.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 11 | 16 | $3,200 | $821.83 | 25.7% |
About Dr. Patrick Reme, MD
Dr. Patrick Reme, MD is a Infectious Disease healthcare provider based in Plantation, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1649265067.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Reme, MD has received a total of $2,829 in payments from pharmaceutical and medical device companies, with $14.64 received in 2024. These payments were reported across 107 transactions from 14 companies. The most common payment nature is "Food and Beverage" ($2,541).
As a Medicare-enrolled provider, Reme has provided services to 1,819 Medicare beneficiaries, totaling 6,118 services with total Medicare billing of $524,194. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Plantation, FL
- Active Since 09/12/2005
- Last Updated 02/05/2013
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1649265067
Products in Payments
- Biktarvy (Drug) $373.76
- AVYCAZ (Drug) $346.22
- DOVATO (Drug) $214.60
- PREZCOBIX (Drug) $201.91
- CABENUVA (Biological) $185.40
- Arikayce (Drug) $143.63
- AngioVac (Device) $143.01
- DARAPRIM (Drug) $137.00
- SYMTUZA (Drug) $99.00
- ZERBAXA (Drug) $88.92
- ISENTRESS (Drug) $74.32
- PREZISTA (Drug) $66.67
- TEFLARO (Drug) $57.75
- Daraprim 30 Tablet in 1 Bottle (Drug) $53.07
- CRESEMBA (Drug) $31.22
- Baxdela (Drug) $22.46
- Xerava (Drug) $21.28
- EGRIFTA (Drug) $20.90
- TRIUMEQ (Drug) $18.84
- NUZYRA (Drug) $17.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.